William P. Mr. Burke Sells 13,056 Shares of Haemonetics Co. (HAE) Stock

Haemonetics Co. (NYSE:HAE) CFO William P. Mr. Burke sold 13,056 shares of the stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $114.33, for a total transaction of $1,492,692.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

William P. Mr. Burke also recently made the following trade(s):

  • On Thursday, October 25th, William P. Mr. Burke sold 841 shares of Haemonetics stock. The shares were sold at an average price of $46.76, for a total transaction of $39,325.16.

HAE opened at $111.61 on Friday. The company has a current ratio of 2.92, a quick ratio of 1.94 and a debt-to-equity ratio of 0.47. The firm has a market cap of $5.95 billion, a price-to-earnings ratio of 59.68, a P/E/G ratio of 3.67 and a beta of 1.09. Haemonetics Co. has a 52-week low of $53.74 and a 52-week high of $117.56.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The firm had revenue of $241.58 million for the quarter, compared to the consensus estimate of $233.44 million. Haemonetics had a net margin of 2.26% and a return on equity of 16.04%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm posted $0.48 earnings per share. On average, research analysts anticipate that Haemonetics Co. will post 2.33 earnings per share for the current fiscal year.

HAE has been the topic of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 7th. Morgan Stanley increased their price objective on shares of Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, August 8th. Barrington Research increased their price objective on shares of Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a report on Thursday, August 9th. TheStreet downgraded shares of Haemonetics from a “b” rating to a “c+” rating in a report on Monday, August 20th. Finally, Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price objective on the stock in a report on Friday, October 12th. One analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company. Haemonetics currently has a consensus rating of “Buy” and an average price target of $113.20.

Several large investors have recently bought and sold shares of HAE. American Century Companies Inc. lifted its stake in shares of Haemonetics by 231.1% in the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock worth $115,243,000 after buying an additional 701,976 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Haemonetics by 49.3% in the second quarter. Renaissance Technologies LLC now owns 1,969,700 shares of the medical instruments supplier’s stock worth $176,643,000 after buying an additional 650,200 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Haemonetics in the third quarter worth about $52,658,000. Robeco Institutional Asset Management B.V. lifted its stake in shares of Haemonetics by 100.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 408,022 shares of the medical instruments supplier’s stock worth $41,674,000 after buying an additional 204,261 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Haemonetics by 40.2% in the third quarter. JPMorgan Chase & Co. now owns 709,853 shares of the medical instruments supplier’s stock worth $81,335,000 after buying an additional 203,656 shares in the last quarter. 96.44% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/11/william-p-mr-burke-sells-13056-shares-of-haemonetics-co-hae-stock.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply